SARS-CoV-2 vaccines in patients with SLE

As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Wei, Askanase, Anca D, Khalili, Leila, Merrill, Joan T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941677/
https://www.ncbi.nlm.nih.gov/pubmed/33685998
http://dx.doi.org/10.1136/lupus-2021-000479
_version_ 1783662175564333056
author Tang, Wei
Askanase, Anca D
Khalili, Leila
Merrill, Joan T
author_facet Tang, Wei
Askanase, Anca D
Khalili, Leila
Merrill, Joan T
author_sort Tang, Wei
collection PubMed
description As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.
format Online
Article
Text
id pubmed-7941677
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79416772021-03-09 SARS-CoV-2 vaccines in patients with SLE Tang, Wei Askanase, Anca D Khalili, Leila Merrill, Joan T Lupus Sci Med Brief Communication As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process. BMJ Publishing Group 2021-03-08 /pmc/articles/PMC7941677/ /pubmed/33685998 http://dx.doi.org/10.1136/lupus-2021-000479 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Brief Communication
Tang, Wei
Askanase, Anca D
Khalili, Leila
Merrill, Joan T
SARS-CoV-2 vaccines in patients with SLE
title SARS-CoV-2 vaccines in patients with SLE
title_full SARS-CoV-2 vaccines in patients with SLE
title_fullStr SARS-CoV-2 vaccines in patients with SLE
title_full_unstemmed SARS-CoV-2 vaccines in patients with SLE
title_short SARS-CoV-2 vaccines in patients with SLE
title_sort sars-cov-2 vaccines in patients with sle
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941677/
https://www.ncbi.nlm.nih.gov/pubmed/33685998
http://dx.doi.org/10.1136/lupus-2021-000479
work_keys_str_mv AT tangwei sarscov2vaccinesinpatientswithsle
AT askanaseancad sarscov2vaccinesinpatientswithsle
AT khalilileila sarscov2vaccinesinpatientswithsle
AT merrilljoant sarscov2vaccinesinpatientswithsle

Ejemplares similares